| Identification | More | [Name]
Rafoxanide | [CAS]
22662-39-1 | [Synonyms]
3'-CHLORO-4'-(4-CHLOROPHENOXY)-3,5-DIIODOSALICYLANILIDE
DIANMILIU'AN RAFOXANIDE
RAFOXANIDE
3’-chloro-4’-(p-chlorophenoxy)-3,5-diiodo-salicylanilid
3’-chloro-4’-(p-chlorophenoxy)-3,5-diiodosalicylanilide
bovanide
duofas
flukanide
mk-990
n-(3-chloro-4-(4-chlorophenoxy)phenyl)-2-hydroxy-3,5-diiodo-benzamid
rafoxanidum
Ranide
Rafoxanide BP V85
Rafoxanide, Vetranal
N-[3-Chloro-4-(4-chlorophenoxy)phenyl]-2-hydroxy-3,5-diiodobenzamide
3''-CHLORO-4''-(4-CHLOROPHENOXY)-3,5-DIIODOSALICYLANILIDE(RAFOXANIDE)
RADIXGLYCYRRHIZAE.P.E
3'-Chloro-4'-(p-chlorophenoxy)-2-hydroxy-3,5-diiodobenzanilide | [EINECS(EC#)]
245-148-9 | [Molecular Formula]
C19H11Cl2I2NO3 | [MDL Number]
MFCD00682899 | [Molecular Weight]
626.01 | [MOL File]
22662-39-1.mol |
| Chemical Properties | Back Directory | [Melting point ]
168-170° | [Boiling point ]
526.6±50.0 °C(Predicted) | [density ]
2.050±0.06 g/cm3(Predicted) | [storage temp. ]
0-6°C | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly) | [form ]
neat | [pka]
6.04±0.48(Predicted) | [color ]
White to Off-White | [Merck ]
14,8097 | [Major Application]
agriculture
environmental | [InChI]
InChI=1S/C19H11Cl2I2NO3/c20-10-1-4-13(5-2-10)27-17-6-3-12(9-15(17)21)24-19(26)14-7-11(22)8-16(23)18(14)25/h1-9,25H,(H,24,26) | [InChIKey]
NEMNPWINWMHUMR-UHFFFAOYSA-N | [SMILES]
C(NC1=CC=C(OC2=CC=C(Cl)C=C2)C(Cl)=C1)(=O)C1=CC(I)=CC(I)=C1O | [CAS DataBase Reference]
22662-39-1(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
White to Off-White Solid | [Uses]
Rafoxanide is a thyroid hormone receptor. | [in vivo]
Rafoxanide (7.5 mg/kg, i.p., once every 2 d for 88d) reduces colonic tumorgenesis in Apcmin/+ mice[3].
| Animal Model: | AOM induced Apcmin/+ mice[3] | | Dosage: | 7.5 mg/kg | | Administration: | Intraperitoneal injection (i.p.), once every 2 d for 88d | | Result: | Exerted less number and size of AOM induced lesions in the colon. No significant body weight changes were observed.
Detected adenomas (28.6%), advanced adenomas (67.8%) and adenocarcinoma (3.6%) in control group as adenomas (33.3%), advanced adenomas (25%%) and no obvious lesions(41.6%) were detected in treated group.
Caused increased signal for p-eIF2α, CHOP and cleaved caspase-3 in tumor tissues while these signal in non-tumor colon epithelium were barely detectable. |
| [IC 50]
Schistosome |
|
|